Pharmacy Times®
Specialty Pharmacy Times
  • Specialty Drugs: Year in Review 2014
  • Are the Political Winds Shifting for Medical Marijuana?
  • The New Paradigm in Specialty: Payer Formulary Control?
  • Managing Care and Costs for Orphan Conditions
  • CMS Under Increased Pressure to Make Accurate Payments for Prescription Drugs
  • Why a Holistic, Technology-Enabled Treatment Approach Is Necessary to Address Hepatitis C–Related Liver Disease
Stem Cell Transplant May Enhance Severe Multiple Sclerosis Treatment
Davy James, Managing Editor
Procedure may be more effective than leading drug mitoxantrone.
Compound May Lead to Improved Leukemia Treatments
Davy James, Managing Editor
Researchers believe drug will lead to ‘new paradigm’ in leukemia therapy.
HIV Patients Benefit from Exercise for Secondary Illnesses
Davy James, Managing Editor
Moderate to intense exercise carries wide range of benefits.
Harvoni by Gilead Sciences, Inc
Michael R. Page, PharmD, RPh
Harvoni is an all-oral treatment of chronic hepatitis C genotype 1 infection in adults.
Viekira Pak by AbbVie Inc
Michael R. Page, PharmD, RPh
Viekira Pak is an all-oral regimen that has been approved by the FDA for the treatment of genotype 1 chronic hepatitis C virus infection.
Featured Video
Drug Adherence Trends in Specialty Pharmacy
Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses adherence trends specialty pharmacies need to be aware of.
Industry Guide
We've created this Industry Guide with close to 300 companies and organizations as a one-stop guide for industry stakeholders in the specialty pharmacy space.
Current Issue
Conference Calendar
â—„        March 2015        â–º
Featured Company Profile
Pharmacy Times
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2015
Intellisphere, LLC. All Rights Reserved.